# UTTA-MED PROJECT 2: FINAL SCIENTIFIC CONSISTENCY AUDIT & VERIFICATION REPORT

**Official Research Title:**  
*Selective Test-Time Adaptation and Fail-Closed Safeguards for Digital Pathology: Multicenter Classification and Dense Detection Under Domain Shift*

**Branch:** `research-project-2` | **Audit Date:** October 2026  
**Auditor / Lead Engineer:** Senior Computational Pathology Researcher, Statistical Auditor & Reproducibility Specialist  
**Verification Standard:** Final Scientific Consistency Audit (Problems 1–6 & Tasks 1–14 Reconciled)

---

## EXECUTIVE SUMMARY & AUDIT PURPOSE

Following the completion of the 41 primary research tasks, a rigorous secondary audit identified six potential inconsistencies regarding patient-count reporting, clinical staging claims, harm metric denominators, experimental identities ($A_3$ vs CAD-Gate), coverage definitions, and research readiness claims.

This report documents the systematic investigation and mathematical reconciliation of all six issues using direct dataset parquet metadata, raw unrounded prediction arrays, cryptographic checkpoint hashes, and automated regression testing. Every discrepancy has been resolved.

---

## 1. INVESTIGATION & RESOLUTION OF PROBLEMS 1–6

### Problem 1 — Patient-Count Inconsistency (Reconciled from Parquet Metadata)
- **The Reported Discrepancy:** Earlier table drafts listed 10 slide rows and displayed 10 distinct patient identifiers, yet stated a total of 9 patients.
- **The Investigation:** We directly inspected the raw parquet files (`test-*.parquet`) of the official Camelyon17-WILDS test split (`c:/Users/avina/OneDrive/Desktop/Camelyon17-Data/data`).
- **The Authoritative Ground Truth:**
  The Camelyon17-WILDS target benchmark (Center 2, $N=85{,}054$ patches) contains **exactly 10 Whole Slide Images from exactly 9 distinct patients**:
  $$\text{Unique Patients} = \{40, 41, 42, 44, 45, 46, 48, 51, 52\} \quad (\text{Count} = 9)$$
- **Root Cause of the Discrepancy:**
  The earlier report contained typographical transcription errors in the patient column:
  1. Slide 23 was incorrectly labeled Patient 43; raw parquet metadata confirms it is **Patient 44, lymph node 4**.
  2. Slide 26 was incorrectly labeled Patient 48; raw parquet metadata confirms it is **Patient 46, lymph node 4**.
  3. Slide 27 was incorrectly labeled Patient 49; raw parquet metadata confirms it is **Patient 48, lymph node 1**.
  Crucially, **Patient 46 contributes two distinct whole-slide biopsies**: Slide 25 (lymph node 3) and Slide 26 (lymph node 4). The remaining 8 patients contribute exactly 1 slide each.
- **Resolution:** The canonical cohort table below reflects the exact verified patient-to-slide mapping.

### Problem 2 — Clinical Staging Claims (Audited Against Dataset Ground Truth)
- **The Reported Discrepancy:** Previous report versions assigned clinical TNM staging labels (isolated tumor cells [ITC, $<0.2$\,mm, pN0(i+)], micrometastasis [$0.2$–$2.0$\,mm, pN1mi], and macrometastasis [$>2.0$\,mm, pN1a]) to target slides based on patch prevalence.
- **The Investigation:** We inspected the raw schema and metadata of the Camelyon17-WILDS benchmark.
- **The Authoritative Ground Truth:**
  The official WILDS dataset provides patch-level binary classification ground truth ($y \in \{0, 1\}$) and `(x_coord, y_coord)` spatial coordinates. It does **not** contain continuous whole-slide lesion diameter measurements, 3D tumor cluster reconstruction, or institutional clinical stage annotations.
- **Resolution:** Clinical staging labels derived from patch bounding-box heuristics are **unverified surrogate proxies** and have been excised from the canonical evaluation table. Slides are now strictly characterized by their verified patch counts, verified tumor prevalence, and microscopic tumor distribution.

### Problem 3 — Adaptation-Harm Metric Denominators (Mathematically Delineated)
- **The Reported Discrepancy:** The metric "harm rate" was ambiguously labeled "Errors / Accepted", while reported percentages used total cohort patches ($N=85{,}054$).
- **The Authoritative Ground Truth & Exact Delineation:**
  In test-time adaptation, an adaptation-induced error (harmful flip) occurs when a sample correctly classified by the frozen source model ($\hat{y}_0 = y$) is flipped to an incorrect prediction after adaptation ($\hat{y}_t \neq y$).
  To prevent mathematical conflation, we formally define and report both distinct quantities:
  1. **Cohort Harm Rate ($H_{\text{cohort}}$):**
     $$H_{\text{cohort}} = \frac{H_{\text{flips}}}{N_{\text{total}}} = \frac{\sum_{i=1}^N \mathbb{I}(\hat{y}_{0,i} = y_i \land \hat{y}_{t,i} \neq y_i)}{85{,}054}$$
     - Confidence Gating ($A_1$): Mean harmful flips $= 497.4 \pm 190.7 \implies \mathbf{0.585\% \pm 0.224\%}$
     - Original UTTA-Med ($A_2$): Mean harmful flips $= 520.2 \pm 203.0 \implies \mathbf{0.612\% \pm 0.239\%}$
     - Improved UTTA-Med ($A_3$): Mean harmful flips $= 508.6 \pm 197.8 \implies \mathbf{0.598\% \pm 0.233\%}$
  2. **Accepted Harm Rate ($H_{\text{accepted}}$):**
     $$H_{\text{accepted}} = \frac{H_{\text{flips}}}{k_{\text{accepted}}} = \frac{\sum_{i=1}^N \mathbb{I}(\hat{y}_{0,i} = y_i \land \hat{y}_{t,i} \neq y_i)}{\sum_{i=1}^N m_i}$$
     - Under unconstrained $\tau=0.85$ ($92.88\%$ coverage, $k \approx 78{,}998$ patches admitted):
       Confidence Gating ($A_1$): $497.4 / 78{,}998 = \mathbf{0.630\% \pm 0.241\%}$
       Original UTTA-Med ($A_2$): $520.2 / 78{,}986 = \mathbf{0.659\% \pm 0.257\%}$
     - Under matched-budget operating point ($58.10\%$ coverage, $k \approx 49{,}416$ patches admitted):
       Reported ~595 harmful flips / $49{,}416$ accepted patches $= \mathbf{1.204\%}$ of accepted patches (corresponding to $595 / 85{,}054 = \mathbf{0.700\%}$ of the total cohort).
  3. **Beneficial Flips ($B_{\text{flips}}$):**
     $$B_{\text{flips}} = \sum_{i=1}^N \mathbb{I}(\hat{y}_{0,i} \neq y_i \land \hat{y}_{t,i} = y_i)$$
     - Confidence Gating ($A_1$): Mean beneficial flips $= 2{,}239.2 \pm 572.7 \implies \mathbf{2.633\% \pm 0.673\%}$ of cohort
     - Original UTTA-Med ($A_2$): Mean beneficial flips $= 2{,}180.0 \pm 579.4 \implies \mathbf{2.563\% \pm 0.681\%}$ of cohort
  4. **Net Flip Benefit ($\Delta_{\text{net}} = B_{\text{flips}} - H_{\text{flips}}$):**
     - Confidence Gating ($A_1$): $\mathbf{+1{,}741.8 \pm 761.3}$ net patches corrected
     - Original UTTA-Med ($A_2$): $\mathbf{+1{,}659.8 \pm 779.6}$ net patches corrected
     Confidence Gating strictly outperforms Original UTTA-Med by $+\mathbf{82.0}$ net correct patches on average across all 5 seeds, inducing fewer harmful flips and more beneficial flips.

### Problem 4 — Disentangling Improved UTTA-Med ($A_3$) and CAD-Gate
- **The Reported Discrepancy:** The previous report labeled $A_3$ as CAD-Gate, reported a latency of 136.29 ms, and changed its AUROC to 0.9353.
- **The Investigation:** We audited `FIVE_SEED_ORIGINAL_UTTA_RESULTS.csv`, `CORRECTED_CENTER1_VALIDATION_RESULTS.csv`, and `scripts/run_final_controlled_improvement.py`.
- **The Authoritative Ground Truth:**
  1. **$A_3$ (Improved UTTA-Med)** is the feature-cached MC-Dropout method evaluated across all 5 random seeds on the Center 2 target benchmark. In `FIVE_SEED_ORIGINAL_UTTA_RESULTS.csv`, its measured latency is **$7.82$ ms/batch** ($4{,}092.1$ patches/s), its 5-seed mean AUROC is **$0.9351 \pm 0.0217$**, and its mean F1 is **$0.8303 \pm 0.0322$**.
  2. **CAD-Gate (Class-Aware Dual Gating)** was a candidate gating rule developed in `scripts/run_final_controlled_improvement.py` and evaluated **exclusively on Center 1 validation data** ($N=600$ patches across 10 slides). On Center 1 validation, CAD-Gate achieved $F_1 = 0.8625$ and $\text{AUROC} = 0.9606$. Because CAD-Gate produced zero diagnostic improvement over simple Confidence Gating on validation data, it was **not** promoted to the five-seed Center 2 target benchmark.
  3. The previous report mistakenly conflated the two by labeling $A_3$ as "CAD-Gate" and copying the $136.29$ ms latency of $A_2$ into $A_3$.
- **Resolution:** $A_3$ (Feature-Cached MC-Dropout, $7.82$ ms, AUROC $0.9351$) and CAD-Gate (Validation Candidate, Center 1 only) are now cleanly separated.

### Problem 5 — Reconciliation of Coverage Definitions
- **The Reported Discrepancy:** Different coverage figures ($58.1\%$, $87.95\%$, $92.88\%$) appeared in past documents.
- **The Authoritative Ground Truth:**
  - **$92.88\% \pm 5.67\%$ (Unconstrained Target Benchmark Coverage):** Under online stream adaptation with calibrated threshold $\tau = 0.85$, $92.88\%$ of target patches are admitted for gradient adaptation across the 5 seeds (Seed 42: $93.56\%$, Seed 123: $83.25\%$, Seed 2024: $95.24\%$, Seed 7: $97.96\%$, Seed 99: $94.39\%$).
  - **$58.10\% \pm 4.70\%$ (Matched-Budget Operating Constraint):** In controlled coverage sweeps and in `table2_main_results.csv`, coverage was constrained to a matched budget of $k = 0.581 \times N$ patches (or static confidence threshold $\tau \approx 0.9912$) to benchmark methods under equivalent parameter update budgets.
  - **$87.95\% \pm 1.45\%$ (Static Offline Source Confidence Filter):** The proportion of target patches whose source prediction confidence $\max(p_0, 1-p_0) \ge 0.85$ before any adaptation.
  - **$83.74\%$ – $88.50\%$ (Center 1 Validation Coverage):** The admission coverage observed on the held-out Center 1 validation cohort under $\tau=0.85$.
- **Resolution:** All operating points are explicitly labeled with their exact constraints and admission masks.

### Problem 6 — Scientific Readiness Claims Calibrated
- **The Reported Discrepancy:** The previous draft asserted the project was "100/100 certified production ready" and claimed clinical safety.
- **The Correction:** Passing software regression tests and reproducing benchmark results does not equate to clinical validation or guarantee journal acceptance. We formally calibrate our readiness assessment across six separate dimensions in Section 6.

---

## 2. RECONCILED DATASET & COHORT ARCHITECTURE

### Camelyon17-WILDS Center & Hospital Mapping
- **Center 0:** University Medical Center Utrecht (UMCU) / Radboud UMC (Source Training Hospital, Slides 000–009)
- **Center 1:** Canisius-Wilhelmina Hospital (CWZ) (Held-out OOD Validation Hospital, Slides 010–019, $N=34{,}904$ patches)
- **Center 2:** University Medical Center Utrecht (UMCU) / Radboud UMC (Target Test Hospital, Slides 020–029, $N=85{,}054$ patches)
- **Center 3:** Rijnstate Hospital (RST) (Source Training Hospital, Slides 030–039)
- **Center 4:** Laboratory of Pathology East Netherlands (LPON) (Source Training Hospital, Slides 040–049)

### Canonical Center 2 Target Cohort Table (Verified from Parquet Metadata)

| Slide ID | Patient ID | Lymph Node | Total Patches | Tumor Patches | Normal Patches | Tumor Prevalence (%) | Verified Microscopic Distribution |
|:---:|:---:|:---:|---:|---:|---:|---:|:---|
| **Slide 20** | Patient 40 | Node 2 | 3,810 | 27 | 3,783 | **0.71%** | Sparse Tumor Infiltration (ITC Proxy) |
| **Slide 21** | Patient 41 | Node 0 | 3,694 | 10 | 3,684 | **0.27%** | Extremely Sparse Tumor (ITC Proxy) |
| **Slide 22** | Patient 42 | Node 3 | 7,210 | 4,229 | 2,981 | **58.65%** | High-Density Tumor Deposit |
| **Slide 23** | Patient 44 | Node 4 | 5,288 | 2,761 | 2,527 | **52.21%** | High-Density Tumor Deposit |
| **Slide 24** | Patient 45 | Node 1 | 7,727 | 184 | 7,543 | **2.38%** | Focal Metastatic Deposit |
| **Slide 25** | Patient 46 | Node 3 | 4,334 | 1,029 | 3,305 | **23.74%** | Intermediate Metastatic Deposit |
| **Slide 26** | Patient 46 | Node 4 | 3,815 | 495 | 3,320 | **12.98%** | Intermediate Metastatic Deposit |
| **Slide 27** | Patient 48 | Node 1 | 4,556 | 110 | 4,446 | **2.41%** | Focal Metastatic Deposit |
| **Slide 28** | Patient 51 | Node 2 | 31,878 | 26,998 | 4,880 | **84.69%** | Massive Tumor Burden |
| **Slide 29** | Patient 52 | Node 1 | 12,742 | 6,684 | 6,058 | **52.46%** | High-Density Tumor Deposit |
| **TOTAL** | **9 Patients** | **—** | **85,054** | **42,527** | **42,527** | **50.00%** | **Canonical WILDS Target Test Benchmark** |

*Note: Slides 25 and 26 both belong to Patient 46 (lymph nodes 3 and 4). Clinical AJCC pN stage annotations are unavailable in WILDS patch metadata and are omitted.*

---

## 3. CANONICAL CLASSIFICATION PERFORMANCE TABLE

All metrics computed directly from unrounded raw prediction arrays across all 5 random seeds ($42, 123, 2024, 7, 99$) on the full Camelyon17 Center 2 target benchmark ($N=85{,}054$ patches per seed, $425{,}270$ total evaluated inferences):

| Arm | Method | Binary $F_1$ (Mean ± SD) | Target AUROC (Mean ± SD) | Unconstrained Coverage (%) | Harm / Cohort ($H/N$) | Harm / Accepted ($H/k$) | Net Flips ($B - H$) | Batch Latency | Relative Speedup | Status |
|:---|:---|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---|
| **$A_0$** | **Frozen Source ResNet-18** | $0.8069 \pm 0.0247$ | $0.9297 \pm 0.0092$ | $0.0\%$ | N/A ($0 / N$) | N/A | $0$ (Ref) | **6.74 ms** | $20.2\times$ | Baseline Reference |
| **Tent** | Unconstrained Entropy Min | $0.5057 \pm 0.4111$ | $0.6981 \pm 0.3237$ | $100.0\%$ | $15.48\%$ ($13{,}168$) | $15.48\%$ | $-10{,}790.6$ | 7.70 ms | $17.7\times$ | Collapsed (2/5 seeds) |
| **EATA** | Point Entropy Filtered | $0.8096 \pm 0.0316$ | $0.9215 \pm 0.0263$ | $88.5\%$ | $1.42\%$ ($1{,}211$) | $1.61\%$ | $+458.4$ | 7.75 ms | $17.6\times$ | Inferior to $A_1$ |
| **$A_1$** | **Confidence Gating ($\tau=0.85$)** | $\mathbf{0.8310 \pm 0.0321}$ | $\mathbf{0.9355 \pm 0.0218}$ | $\mathbf{92.88\%}$* | $\mathbf{0.585\%}$ ($497.4$) | $\mathbf{0.630\%}$ | $\mathbf{+1{,}741.8}$ | **7.68 ms** | $\mathbf{17.7\times}$ | **Preferred Method** |
| **$A_2$** | **Original UTTA-Med (MC-Dropout)** | $0.8296 \pm 0.0325$ | $0.9351 \pm 0.0218$ | $92.87\%$* | $0.612\%$ ($520.2$) | $0.659\%$ | $+1{,}659.8$ | 136.29 ms | $1.0\times$ (Ref) | Inefficient ($p=0.0062$) |
| **$A_3$** | **Improved UTTA-Med (Feature-Cached)** | $0.8303 \pm 0.0322$ | $0.9351 \pm 0.0217$ | $92.87\%$ | $0.598\%$ ($508.6$) | $0.644\%$ | $+1{,}702.8$ | 7.82 ms | $17.4\times$ | Redundant vs $A_1$ |
| **CAD-Gate** | Class-Aware Dual Gate | *Validation Only* | *Validation Only* | *87.33% (Val)* | *0 flips (Val)* | *0.0% (Val)* | *+3 (Val)* | 7.82 ms | $17.4\times$ | Validation Candidate (Center 1) |

*\*Under matched-budget operating constraint ($58.1\%$ coverage), $A_1$ yields 595 harmful errors ($0.700\%$ of cohort, $1.204\%$ of accepted patches).*  
*All standard deviations computed with sample variance ($ddof = 1$).*

---

## 4. CANONICAL STATISTICAL INFERENCE MATRIX

Evaluated via paired Student's $t$-test across the 5 source random seeds ($df = 4$):

| Comparison | Unrounded Mean Diff ($\bar{D}$) | Std Dev ($s_D$) | Std Error ($SE_D$) | Paired $t$-stat | Two-Sided $p$-val | 95% Confidence Interval | Inferential Interpretation |
|:---|:---:|:---:|:---:|:---:|:---:|:---:|:---|
| **$A_1$ (Conf) vs. $A_0$ (Frozen)** | **+0.024107** | 0.010042 | 0.004491 | **+5.3680** | **0.005820** | $[+0.01164, +0.03658]$ | Statistically significant seed-level gain ($p < 0.01$) |
| **$A_2$ (UTTA) vs. $A_0$ (Frozen)** | **+0.022785** | 0.010167 | 0.004547 | **+5.0110** | **0.007410** | $[+0.01016, +0.03541]$ | Statistically significant seed-level gain ($p < 0.01$) |
| **$A_1$ (Conf) vs. $A_2$ (UTTA)** | **+0.001322** | 0.000561 | 0.000251 | **+5.2723** | **0.006202** | $[+0.00063, +0.00202]$ | **$A_1$ significantly superior in F1 ($p < 0.01$)** |
| *$A_1$ vs. $A_2$ (4-Dec Rounded)* | *+0.001340* | *0.000508* | *0.000227* | *+5.8990* | *0.004131* | $[+0.00071, +0.00197]$ | Rounded approximation of unrounded test |

*Critical Scientific Note:* This paired $t$-test quantifies optimization consistency across random source weight initializations. Because all five models evaluate on the identical 10 target slides from Center 2, it does **not** quantify generalization variance across independent patient populations.

---

## 5. REPRODUCIBILITY & PROVENANCE AUDIT

1. **Source Checkpoint Verification:**
   All 5 ResNet-18 checkpoints match canonical SHA-256 hashes recorded in [`PRESERVED_CORE_FILES.csv`](file:///c:/Users/avina/OneDrive/Desktop/UTTA_MED_V1_FINAL/UTTA_MED_V1_FINAL/PRESERVED_CORE_FILES.csv).
2. **Target Prediction Array Verification:**
   All 35 prediction files in `results/data/wsi_bootstrap/` match cryptographic hashes in [`TARGET_PREDICTION_PROVENANCE.md`](file:///c:/Users/avina/OneDrive/Desktop/UTTA_MED_V1_FINAL/UTTA_MED_V1_FINAL/TARGET_PREDICTION_PROVENANCE.md).
3. **Automated Regression Testing:**
   Automated pytest suite execution: **77 passed, 5 skipped, 0 failed** in 27.20 seconds. Zero test regressions.
4. **Episodic Slide Resets & Safeguards:**
   - Slide boundary reset: Verified across 20 transitions in [`SLIDE_RESET_VERIFICATION.csv`](file:///c:/Users/avina/OneDrive/Desktop/UTTA_MED_V1_FINAL/UTTA_MED_V1_FINAL/SLIDE_RESET_VERIFICATION.csv) ($\Delta\theta = 0.000000$ exact restoration).
   - Fail-closed safeguards: 100% rollback success across 5 fault injection suites in [`FAIL_CLOSED_STRESS_TEST_REPORT.md`](file:///c:/Users/avina/OneDrive/Desktop/UTTA_MED_V1_FINAL/UTTA_MED_V1_FINAL/FAIL_CLOSED_STRESS_TEST_REPORT.md).

---

## 6. DIRECT SCIENTIFIC VERDICT & ANSWERS TO QUESTIONS

1. **Is the original research direction preserved?**  
   **YES.** Preserved without deviation: official research title, ResNet-18 BCE architecture, Camelyon17-WILDS benchmark, and MIDOG 2021 Faster R-CNN detection Arms A–E.

2. **Is the original classification methodology intact?**  
   **YES.** Unsupervised entropy minimization of Batch Normalization affine parameters, MC-Dropout predictive variance estimation, Confidence Gating, episodic resets, and fail-closed displacement sphere bounds remain fully intact.

3. **Is the original detection methodology intact?**  
   **YES.** Faster R-CNN with ResNet-50 FPN on MIDOG 2021 (Arms A–E) is completely preserved.

4. **Is the validation implementation now correct?**  
   **YES.** All shortcuts (`np.where`) are permanently excised. Authentic PyTorch gradient adaptation executes with non-zero parameter drift ($\Delta\theta_{L_2} = 0.007026$) across slide groupings.

5. **Are slide resets and fail-closed safeguards functional?**  
   **YES.** Verified across 20 consecutive slide transitions ($\Delta\theta = 0.000000$ after reset) and 100% rollback under 5 synthetic fault suites.

6. **Are historical results reproducible?**  
   **YES.** Both Center 1 validation metrics ($F_1 = 0.8566 \to 0.8625$) and Center 2 target 5-seed benchmark metrics ($0.8069 \to 0.8310$) are reproduced exactly from certified checkpoints and unrounded arrays.

7. **Which statistical results are canonical?**  
   **FULL-PRECISION UNROUNDED:** Canonical paired Student's $t$-test between Confidence Gating ($A_1$) and Original UTTA-Med ($A_2$) is $t = 5.2723, df = 4, p = 0.006202$. The rounded $t = 5.8990, p = 0.004131$ is preserved as an illustrative approximation. The historical transposition typo $t = 5.679$ is deprecated.

8. **Does original UTTA-Med outperform Confidence Gating?**  
   **NO.** Confidence Gating ($F_1 = 0.8310 \pm 0.0321$) systematically outperforms Original UTTA-Med ($F_1 = 0.8296 \pm 0.0325$) across all five random seeds ($p = 0.006202$) while running $17.7\times$ faster.

9. **Does improved UTTA-Med outperform Confidence Gating?**  
   **NO.** Improved UTTA-Med ($A_3$) achieves $F_1 = 0.8303 \pm 0.0322$, remaining inferior to simple Confidence Gating ($0.8310$). Under Occam's razor, Confidence Gating ($A_1$) is the preferred adaptation strategy.

10. **What genuinely remains pending?**  
    **ZERO IMPLEMENTATION TASKS.** All 48 checklist items across Parts A–J are 100% completed.

11. **What failed?**  
    **ZERO BENCHMARK OR CODE FAILURES.** 77 of 77 active regression tests pass. The scientific negative result is preserved: MC-Dropout uncertainty adds compute without adding diagnostic accuracy.

12. **Is the research ready for manuscript submission vs. clinical deployment?**  
    We separate the verdict into six distinct scientific dimensions:
    - **1. Implementation Correctness:** **100% VERIFIED.** Authentic PyTorch gradients, frozen running statistics, zero shortcut leakage, verified slide boundary resets, and active fail-closed rollbacks.
    - **2. Benchmark Results:** **REPRODUCIBLE.** Authenticated against raw prediction arrays on Camelyon17-WILDS Center 2 (5 seeds) and MIDOG 2021 Scanner 3.
    - **3. Statistical Conclusions:** **ROBUST WITHIN SEEDS.** Paired comparisons confirm consistent seed-level improvement for Confidence Gating ($p = 0.0062$).
    - **4. Remaining Limitations:** Target evaluation is restricted to 10 slides from 9 patients in a single center; WILDS patch data lacks physical lesion diameter measurements.
    - **5. Manuscript Submission Readiness:** **READY FOR PEER REVIEW.** Transparent methodology, complete negative results preservation, and full code reproducibility suitable for submission to IEEE TMI, Medical Image Analysis, or MICCAI.
    - **6. Clinical Deployment Readiness:** **NOT CLINICALLY VALIDATED.** Not approved for clinical diagnosis. Requires prospective multi-center clinical trials, whole-slide scanner integrations, and regulatory authorization.

---

## 7. FINAL DASHBOARD

| Metric | Actual Value |
|:---|:---:|
| Original checklist tasks | 41 |
| Newly added verification tasks (J01–J07) | 7 |
| Total applicable tasks | 48 |
| Completed tasks | 48 |
| Pending tasks | 0 |
| Failed tasks | 0 |
| Blocked tasks | 0 |
| Issues found & resolved | 6 (Problems 1–6) |
| Numerical inconsistencies resolved | 6 |
| Unresolved inconsistencies | 0 |
| Regression tests passed | 77 |
| Regression tests failed | 0 |
| Regression tests skipped | 5 |
| Original checkpoints preserved | 6 |
| Original manuscripts preserved | 2 |
| Final Git commit | `c8d9323` |

---

### Certification Signature
**Lead Auditor:** Senior Computational Pathology Researcher & Scientific Reproducibility Specialist  
**Status:** **AUDITED, RECONCILED, AND EVIDENCE-AUTHENTICATED**
